Recent Updates
Recently added Catalysts
CODX Positive Sentiment Score: 70/100

Co-Diagnostics, Inc. Announces Second Quarter 2025 Earnings Release Date and Webcast

Key Takeaway: Co-Diagnostics, Inc. announced it will release its second quarter 2025 financial results on August 14, 2025, after market close. The company will hold a conference call and webcast at 4:30 p.m. ET on the same day to discuss these results with analysts. Key management, including the CEO, CFO, and Head of Investor Relations, will participate in the call. This event demonstrates the company's commitment to transparency and stakeholder engagement.

Market Sentiment Analysis

POSITIVE FACTORS

  • Co-Diagnostics has scheduled a specific date for their Q2 earnings release.
  • The company is actively engaging with analysts through a conference call and webcast.
  • The announcement indicates transparency and communication with stakeholders.

Full Press Release Details

SALT LAKE CITY, July 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2025 financial results on Thursday, August 14, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.
The conference call and webcast will be available via:
Webcast: ir.co-dx.com on the Events & Webcasts page, or accessible directly here
Conference Call: 888-880-3330 (Toll Free) or (646) 357-8766 (Toll)
If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease.
SOURCE Co-Diagnostics

21 %

more press release views with

Frequently Asked Questions

When will Co-Diagnostics release its Q2 2025 financial results?

Co-Diagnostics will release its Q2 2025 financial results on August 14, 2025.

What time is the conference call for Co-Diagnostics?

The conference call is scheduled for 4:30 p.m. ET on August 14, 2025.

How can I access the Co-Diagnostics conference call?

Access the call via the toll-free number 888-880-3330 or 646-357-8766.

Will the conference call be available later?

Yes, the call will be recorded and available later on the Company's website.

What does Co-Diagnostics specialize in?

Co-Diagnostics specializes in molecular diagnostics and develops diagnostic tests.

Last updated: Jul 31, 2025